References
- Almuradova E, Cicin I. Cancer-related hypercalcemia and potential treatments. Front Endocrinol 2023;14:1039490.
- Jick S, Li L, Gastanaga VM, Liede A. Prevalence of hypercalcemia of malignancy among cancer patients in the UK: Analysis of the Clinical Practice Research Data link database. Cancer Epidemiol 2015;39:901-7.
- Burt ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg 1980;115:704-7.
- Goldner W. Cancer-related hypercalcemia. J Oncol Pract 2016;12:426-32.
- Walker MD, Shane E. Hypercalcemia: A review. JAMA 2022;328:1624-36.
- Guise TA, Wysolmerski JJ. Cancer-associated hypercalcemia. N Engl J Med 2022;386:1443-51.
- Mirrakhimov AE. Hypercalcemia of malignancy: An update on pathogenesis and management. N Am J Med Sci 2015;7:483.
- Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. QJM 1981;50:473-81.
- Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974;34:1268-71.
- Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990;46:S26-30.
- Austin LA, Heath 3rd H. Calcitonin: Physiology and pathophysiology. N Engl J Med 1981;304:269-78.
- Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al. Basic research and clinical applications of bisphosphonates in bone disease: What have we learned over the last 40 years? J Transl Med 2013;11:1-8.
- Russell RG, Xia Z, Dunford JE, Oppermann UD, Kwaasi A, Hulley PA, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57.
- Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: Mechanism of action and clinical outcomes. Int J Clin Pract 2012;66:1139-46.
- Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
- Warrell RP, Bockman RS, Coonley CJ, Isaacs M, Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984;73:1487-90.
- Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006;12:47-53.
- Adams JS. Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin N Am 1989;18:765-78.
- Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano C, et al. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient’s opinion. Br J Dermatol 2007;157:142-8.
- Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996;72:424-8.
- Leehey DJ, Ing TS. Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis 1997;29:288-90.
- Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: Morbidity and mortality: Clinical experience in 126 treated patients. Ann Intern Med 1990;112:499-504.
- Ling PJ, A’Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995;72:206-9.
- Gupta S, Rastogi A, Singh P, Chophy A, Roushan R, Krishnan AS, et al. Treatment outcomes and survival in hypercalcemia of malignancy: A grave metabolic emergency. Cureus 2023;15:e35783.
- Ramos RE, Perez Mak M, Alves MF, Piotto GH, Takahashi TK, Gomes da Fonseca L, et al. Malignancy-related hypercalcemia in advanced solid tumors: Survival outcomes. J Glob Oncol 2017;3:728-33.
- Penel N, Dewas S, Doutrelant P, Clisant S, Yazdanpanah Y, Adenis A. Cancer-associated hypercalcemia treated with intravenous diphosphonates: A survival and prognostic factor analysis. Support Care Cancer 2008;16:387-92.
- Penel N, Dewas S, Hoffman A, Adenis A. Cancer-associated hypercalcemia: Validation of a bedside prognostic score. Support Care Cancer 2009;17:1133-5.
- Feldenzer KL, Sarno J. Hypercalcemia of malignancy. J Adv Pract Oncol 2018;9:496.
- Vakiti A, Anastasopoulou C, Mewawalla P. Malignancy-related hypercalcemia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2018.
- Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322-34.
- Soyfoo MS, Brenner K, Paesmans M, Body JJ. Non-malignant causes of hypercalcemia in cancer patients: A frequent and neglected occurrence. Support Care Cancer 2013;21:1415-9.
- Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Ragni A, Zanata I, et al. What lies behind paraneoplastic hypercalcemia secondary to well-differentiated neuroendocrine neoplasms? A systematic review of the literature. J Pers Med 2022;12:1553.
- Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Guarnotta V, Ragni A, et al. Case report: Unmasking hypercalcemia in patients with neuroendocrine neoplasms. Experience from six Italian referral centers. Front Endocrinol 2021;12:665698.
- Altieri B, Di Dato C, Modica R, Bottiglieri F, Di Sarno A, Pittaway JF, et al. Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors. Nutrients 2020;12:1021.
- Degardin M, Nguyen M, Beaurin D, Lesoin A, Fournier C, Lefebvre JL, et al. Hypercalcemia and squamous cell carcinoma of the upper respiratory-digestive tracts. Incidence and prognosis. Bull Cancer 1995;82:975-80.